A new study has linked moderate-to-severe obstructive sleep apnea (OSA), characterized by low oxygen levels overnight, with an increased risk of developing wet age-related macular degeneration (AMD).
Prevent Blindness announces its fourth annual Geographic Atrophy Awareness Week, December 2 to 8, 2024. The organization ...
Post hoc analyses of the AREDS / AREDS2 studies presented at the recent American Academy of Ophthalmology meeting examined supplementation on the risk of geographic atrophy progression.
Prevent Blindness, the nation's leading nonprofit eye health organization, is announcing Dec. 2-8, 2024, as its fourth annual Geographic Atrophy (GA) Awareness Week. GA is an advanced form of dry ...
Findings from a post hoc analysis of the AREDS and AREDS2 studies were presented at the recent American Academy of ...
HAYWARD, CA, USA I1, 2024 I Avirmax Biopharma, Inc., a leader in the development of innovative gene therapies, today announced that the first ...
The US FDA has issued a CRL for sNDA of Astellas Pharma’s IZERVAY, a treatment for geographic atrophy (GA) secondary to AMD.
The FDA issued a Complete Response Letter (CRL) for Astellas' Izervay, which is intended to treat geographic atrophy (GA), a ...
Ocugen (OCGN) announced positive preliminary efficacy and safety data from the Phase 1 dose-escalation portion of the Phase 1/2 OCU410 ArMaDa ...
Ocugen (NASDAQ:OCGN) reported positive Phase 1 data for its gene therapy candidate OCU410 in the treatment of geographic ...